Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study

Basit Öğe Kaydı
dc.authoridUysal, Mukremin/0000-0002-8524-0665
dc.authoridBeypınar, İsmail/0000-0002-0853-4096
dc.authoridKESKİNKILIÇ, MERVE/0000-0002-3342-3144
dc.contributor.authorBeypinar, Ismail
dc.contributor.authorDemir, Hacer
dc.contributor.authorYaslikaya, Sendag
dc.contributor.authorKoeseci, Tolga
dc.contributor.authorDemir, Bilgin
dc.contributor.authorColak, Gokhan
dc.contributor.authorAgaoglu, Ahmet Burak
dc.date.accessioned2024-08-31T07:48:19Z
dc.date.available2024-08-31T07:48:19Z
dc.date.issued2024
dc.departmentEge Üniversitesien_US
dc.description.abstractPurpose In advanced breast cancer, endocrine therapy is preferred in the absence of visceral crisis. Cyclin-dependent kinase inhibitors (CDKi) are the gold standards. The selection of subsequent treatments after CDKi treatment is still controversial, and the efficacy of everolimus (EVE) combinations is unknown. In this study, we aimed to investigate the efficacy of EVE after CDKi administration in real-life experiences. Method The study received data from 208 patients from 26 cancer centers. Demographic and histologic features, diagnosis, progression, last visit dates, and toxicities were recorded. This study was a retrospective case series. Results One hundred and seven patients received palbociclib, while 101 patients received ribociclib as a CDKi. The overall response and disease control rates of EVE combinations were 60% and 88%, respectively. In univariate analysis, the absence of liver metastasis, age > 40 years, better type of response, and immediate treatment after CDKi were related to increased progression-free survival. Liver metastasis and response type were significantly associated with overall survival. In the multivariate analysis, response remained significant in terms of progression-free survival, while response type, liver metastatic disease, and hematologic toxicity were prognostic in terms of overall survival. Conclusion This study provides evidence of the benefits of EVE combinations after CDKi treatment. EVE combinations may be more appropriate for patients with non-liver metastasis, and the first treatment response shows the benefit of treatment. In addition, immediate treatment after CDKi treatment is more beneficial than later lines of treatment.en_US
dc.description.sponsorshipDAS:The data is available if requested.en_US
dc.identifier.doi10.1007/s10549-024-07456-x
dc.identifier.issn0167-6806
dc.identifier.issn1573-7217
dc.identifier.pmid39123071en_US
dc.identifier.scopus2-s2.0-85200995079en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1007/s10549-024-07456-x
dc.identifier.urihttps://hdl.handle.net/11454/104733
dc.identifier.wosWOS:001288064700001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofBreast Cancer Research and Treatmenten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240831_Uen_US
dc.subjectEverolimusen_US
dc.subjectBreast Canceren_US
dc.subjectCyclin-Dependent Kinase Inhibitorsen_US
dc.subjectPalbocicliben_US
dc.subjectRibocicliben_US
dc.subjectLife Experienceen_US
dc.titleEfficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu